CARBOGEN AMCIS announces major investments of which more than 45 million euros on the Biopôle Clermont-Limagne.
Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient and drug products manufacturing company, announced new expansion plans in Switzerland and France.
The company is planning a major expansion project of its French site that will increase manufacturing capacity to better meet the expectations of the current market and its customers. Construction of a new production unit will begin in January 2021 and the first production is planned for the first quarter of 2023. This project totals an investment of more than 45 million euros, in a context of more than six years of constant growth for the company.
The new building will be built on the Biopôle Clermont-Limagne site in Saint-Beauzire. This new facility will be dedicated to the manufacture of injectable products, both for the supply of clinical and commercial batches and will be able to treat complex formulations that can implement a wide range of different types of active ingredients, both chemical and biological.
Located on a plot of over 14,000 m2, this two-storey building with a surface area of 9,500 m2 will include a large area of research and development and quality control laboratories, while production will be ensured by two aseptic filling lines under state-of-the-art insulator. In addition, a new office space will accommodate the various administrative functions. The building will also have additional space for future expansion.
CARBOGEN AMCIS, which currently employs around 40 people in the Puy-de-Dôme, plans to open between 60 and 70 new positions.
This expansion project is part of a global strategic growth plan of CARBOGEN AMCIS which is also investing in the creation of a new production plant in Switzerland.